A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
455actual
Sites
1
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-29 | actual | When the study began enrolling |
| Primary completion | 2025-09-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-22 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Epilepsy
- Seizures
Intervention
- Drug: Sodium valporate — also filed as Depakine®
Primary outcomes
what the primary-completion date above is the date OFPercentage of healthcare professionals who received and read the educational materials
measured 7 months
Healthcare professionals' knowledge score
measured 7 months
Healthcare professionals' behavior score
measured 7 months
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed